Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hepatitis C Publisher



Niaz K2 ; Khan F3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacy, University of Malakand, Chakdara, Pakistan
  2. 2. Department of Pharmacology and Toxicology, Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur, Pakistan
  3. 3. Department of Toxicology and Pharmacology, The Institute of Pharmaceutical Sciences, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Influence of Nutrients# Bioactive Compounds# and Plant Extracts in Liver Diseases Published:2020


Abstract

Hepatitis C infection is a major cause of chronic liver diseases with the potential of liver fibrosis and cirrhosis. So far, an effective vaccine for hepatitis C virus (HCV) prevention is unavailable; however, several drugs are used for the treatment of this infection. Initially, alpha interferon and ribavirin were mainly used but with the advent of directly acting antivirals, HCV therapeutic options have dramatically improved, especially for genotype 1. However, these drugs are expensive and resistance develops to their use. Therefore, there is a need to develop more effective antivirals or a combination of drugs that targets different stages of the life cycles of the virus. In past decades, we have observed an increase in the study of plant-based compounds that are active against microbes that cause diseases in humans. Worldwide, several natural compounds have exhibited antiviral activity as well as anti-HCV activity. In this scenario, plant origin compounds can serve as alternatives for new antiviral drug development. For this purpose, this chapter aims to summarize all possible hepatoprotective activities of natural products and plant extracts that lessen hepatitis C. © 2021 Elsevier Inc. All rights reserved.
Related Docs
View other Related Docs
1. Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A Ns5b Phylogenetic Analysis With Systematic Review, Hepatitis Monthly (2016)
2. Treatment Related Hematologic Changes in a Population of Iranian Patients With Chronic Hepatitis C Infection From 2009 to 2014, Iranian Journal of Public Health (2017)
3. Evaluating the Safety and Efficacy of Silymarin in Β-Thalassemia Patients: A Review, Hemoglobin (2015)
4. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)
5. Correlation Study Between Il-28B Gene Polymorphism (Rs8099917snp) and Sustained Virological Response in Iranian Patients With Chronic Hepatitis C, Clinical Laboratory (2016)
6. Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study, The Lancet Gastroenterology and Hepatology (2017)
7. Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of Who (Emro): A Systematic Review and Meta-Analysis, Hepatitis Monthly (2016)
8. Quercetin May Reduce the Risk of Developing the Symptoms of Covid-19, Avicenna Journal of Phytomedicine (2024)
Experts (# of related papers)
View all Related Experts
Hossein Poustchi (4)
Reza Malekzadeh (2)
Other Related Docs
9. Interferon-Λpolymorphisms and Response to Pegylated Interferon in Iranian Hepatitis C Patients, World Journal of Gastroenterology (2015)
10. Prevalence of Hepatitis C Virus Infection Among High-Risk Groups in Iran: A Systematic Review and Meta-Analysis, Public Health (2018)
11. Evaluation of a Novel Enzyme-Linked Immuno Assay Model to Detect E2 Antigen and Antibodies Against Core, Ns3, Ns4, and Ns5 Antigens of Hepatitis C Virus, Hepatitis Monthly (2020)
12. The Relationship Between Hla-G and Viral Loads in Non-Responder Hcv-Infected Patients After Combined Therapy With Ifn-Α2α and Ribavirin, Human Immunology (2015)
13. Safely Treating Hepatitis C in Patients With Hiv or Hepatitis B Virus Coinfection, Expert Opinion on Drug Safety (2015)
14. Global Change in Hepatitis C Virus Prevalence and Cascade of Care Between 2015 and 2020: A Modelling Study, The Lancet Gastroenterology and Hepatology (2022)
15. An Updated Systematic Review and Metaanalysis on Efficacy of Sofosbuvir in Treating Hepatitis C-Infected Patients With Advanced Chronic Kidney Disease, PLoS ONE (2021)
16. Differential Regulation of Cd4+ T Cell Subsets by Silymarin in Vitro and in Ovalbumin Immunized Mice, DARU# Journal of Pharmaceutical Sciences (2018)
17. Genotype-Related Variations in Proinflammatory and Regulatory Cytokine Levels in Treated and Treatment-Naive Hcv-Infected Patients, Medical Microbiology and Immunology (2018)
18. Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials, Hepatitis Monthly (2016)
19. Estimation of Direct and Indirect Effects of Risk Behaviors on Hcv Infection Among People Who Inject Drugs in Kermanshah, Iran: A Path Analysis Study, Journal of Substance Use (2020)
20. Historical Epidemiology of Hepatitis C Virus (Hcv) in Select Countries - Volume 3, Journal of Viral Hepatitis (2015)
21. A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019, New Microbes and New Infections (2021)
22. Update on Transmission Modes of Hepatitis C Virus Among Volunteer Iranian Blood Donors: Analysis of a Matched Case-Control Study by Penalized Conditional Logistic Regression, Hepatitis Monthly (2018)